Comprehensive treatment based on surgery remains the major pillar for hepatocellular carcinoma (HCC) management. Nevertheless, due to the poor early diagnosis rate, most HCC patients are diagnosed with intermediate-to-advance-stage diseases, losing the opportunity for radical resection. Evidence from the literature showed that only 20–30% of this patient population are candidates for radical resection when initially diagnosed. The first cause of unresectable HCC is the advanced stage of the tumor, where surgical resection generates no benefit or is less effective than other comprehensive treatments. Insufficient future liver remnant (FLR) and decompensated liver function are the second and third causes. Current guidelines recommend that the FLR/SLV (standard liver volume) ratio among patients without underlying liver disease should be greater than 20–30%. In contrast, those with underlying hepatic conditions should be greater than 30–40% [1, 2]. To address the concern of unresectability caused by insufficient FLR in HCC, portal vein embolization (PVE) on the affected side is usually applied to increase the volume of FLR in the earlier years. However, it takes a long time for liver growth with suboptimal increments. In 2007, Hans J. Schlitt et al. took the lead in performing staged hepatectomy combined with liver partition and portal vein ligation (PVL). In 2012, the procedure was named ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) [3]. ALPPS integrates PVL of the affected side and liver parenchyma partition, rapidly promoting FLR growth and improving the resection rate. According to a systematic review [4], for HCC patients undergoing ALPPS, the growth rate of FLR reached 54.9% on the 11th-day average, 98% of patients completed the second stage of liver resection with a total complication rate of approximately 38%, and 3-year and 5-year overall survival (OS) rates standing at 60.2% [5] and 46.8% [6], respectively.